Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Res ; 60(17): 4709-13, 2000 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-10987273

RESUMO

beta-Catenin is a multifunctional molecule with important roles in intercellular adhesion and signal transduction. We reported previously that beta-catenin is mutated in human prostate cancer. In this study, we investigated the role of beta-catenin mutations on androgen receptor (AR) signaling. beta-Catenin significantly enhanced androgen-stimulated transcriptional activation by the AR. beta-Catenin also increased AR transcriptional activation by androstenedione and estradiol and diminished the antagonism of bicalutamide. Coimmunoprecipitation of beta-catenin with AR from LNCaP prostate cancer cells showed that the two molecules are present in the same complex. The amount of beta-catenin in complex with AR was increased by androgen. These findings implicate beta-catenin in the regulation of AR function and support a role for beta-catenin mutations in the pathogenesis of prostate cancer.


Assuntos
Proteínas do Citoesqueleto/fisiologia , Receptores Androgênicos/fisiologia , Transativadores , Ativação Transcricional/fisiologia , Antagonistas de Androgênios/farmacologia , Androgênios/fisiologia , Proteínas do Citoesqueleto/genética , Proteínas do Citoesqueleto/metabolismo , Humanos , Ligantes , Masculino , Mutação , Neoplasias da Próstata/genética , Neoplasias da Próstata/metabolismo , Receptores Androgênicos/genética , Receptores Androgênicos/metabolismo , Especificidade por Substrato , Células Tumorais Cultivadas , beta Catenina
2.
Cancer ; 83(6): 1231-6, 1998 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-9740090

RESUMO

BACKGROUND: Interleukin-2 (IL-2) is used in the treatment of solid tumors and hematologic malignancies. Sudden death is a rare complication of IL-2 treatment. METHODS: A patient with lymphoma underwent chemoradiotherapy myeloablation and autologous stem cell transplantation. The stem cells were cultured in IL-2 (6000 IU/mL) for 24 hours prior to infusion. After engraftment, treatment with IL-2 (1.8 x 10(6) IU/m2/day administered subcutaneously) was begun. After 4 days of treatment, the patient suddenly died. An autopsy was performed. RESULTS: Histologic examination of the myocardium revealed a diffuse, lymphocytic infiltrate with scattered, multinucleated giant cells and foci of myocardial degeneration consistent with giant cell myocarditis. The lymphocytes were predominantly CD4 positive T cells, and the majority of these cells stained with antibodies for perforin, suggesting an unusual cytolytic role for these lymphocytes. DNA end-labeling of myocardial tissue sections revealed numerous apoptotic myocytes within the lymphocytic infiltrate. CONCLUSIONS: To the authors' knowledge, this is the first report of giant cell myocarditis in association with high dose chemotherapy, transplantation, and IL-2 immunomodulation. The authors suggest that the cytokine imbalance produced by IL-2 may have initiated a preferential activation of T helper cells and an autoimmune phenomenon manifesting as giant cell myocarditis.


Assuntos
Antineoplásicos/efeitos adversos , Transplante de Medula Óssea , Células Gigantes/patologia , Transplante de Células-Tronco Hematopoéticas , Interleucina-2/efeitos adversos , Linfoma Folicular/terapia , Miocardite/patologia , Antineoplásicos/uso terapêutico , Apoptose , Evolução Fatal , Feminino , Humanos , Interleucina-2/uso terapêutico , Pessoa de Meia-Idade , Transplante Autólogo
3.
Cancer Res ; 58(12): 2520-3, 1998 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-9635571

RESUMO

Beta-catenin plays essential roles in both intercellular adhesion and signal transduction. As a signaling molecule, beta-catenin supplies an activating domain to the T-cell factor/lymphoid enhancer-binding factor family of DNA-binding proteins and activates gene transcription. Posttranslational stabilization of beta-catenin, leading to elevated protein levels and constitutive gene activation, has been proposed as an important step in oncogenesis. Stabilization of beta-catenin can occur through mutation to highly conserved amino acids encoded in exon 3 of the beta-catenin gene (CTNNB1). To determine whether this pathway of malignant transformation is important in prostate cancer, we analyzed 104 prostate cancer tissue specimens, 4 prostate cancer cell lines, and 3 prostate tumor xenografts for activating mutations in exon 3 of CTNNB1. Mutations were detected in 5 of the 104 prostate cancer tissue samples. Four of the five mutations involved serine or threonine residues implicated in the degradation of beta-catenin. A fifth tumor had a mutation at codon 32, changing a highly conserved aspartic acid to a tyrosine. Mutational analysis of multiple regions from several tumor samples showed that the beta-catenin mutations were present focally and therefore may occur during tumor progression.


Assuntos
Proteínas do Citoesqueleto/genética , Proteínas de Neoplasias/genética , Mutação Puntual/genética , Neoplasias da Próstata/genética , Transativadores , Éxons/genética , Humanos , Masculino , Polimorfismo Conformacional de Fita Simples , Neoplasias da Próstata/química , beta Catenina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...